1. “Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec”.
PUBLISHED: Vaccine. July 11, 2024. https://doi.org/10.1016/j.vaccine.2024.04.089
Editorial comment: A multicomponent strategy to improve HPV vaccination among children in schools from Quebec.
2 “Accelerating Global Measles and Rubella Eradication—Saving Millions of Lives, Preventing Disability, and Averting the Next Pandemic”.
PUBLISHED: Vaccines. June 20, 2024. https://doi.org/10.3390/vaccines12060699
Editorial comment: In response to the rising number of measles cases and outbreaks globally, there is a need to accelerate immunization programs and implement additional epidemiological measures.
3. “COVID-19 Booster Vaccination Status and Long COVID in the United States: A Nationally Representative Cross-Sectional Study”.
PUBLISHED: Vaccines. June 20, 2024. https://doi.org/10.3390/vaccines12060688
Editorial comment: Few studies have explored the association of booster doses on severe disease outcomes and long COVID. This cross-sectional analysis used data from the 2022 US National Health Interview Survey data to investigate how vaccination status correlates with COVID-19 infection severity and long COVID among previously infected individuals. Their results showed that by having at least one booster there was a reduction in long COVID odds by 24% (aOR = 0.76, p = 0.003), however, completing only the primary vaccine series did not significantly decrease the likelihood of severe illness or long COVID. These findings support the continued promotion of booster vaccinations to mitigate long COVID risks in vulnerable populations.
4. “Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus”.
PUBLISHED: Front Immunol. June 20, 2024. https://doi.org/10.3389/fimmu.2024.1376395
Editorial comment: Early pre-clinical but promising results of a combined Influenza and RSV mucosal vaccine in mice.
5. “The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens”.
PUBLISHED: Vaccine. June 13, 2024. https://doi.org/10.1016/j.vaccine.2024.06.017
Editorial comment: An insightful review on how vaccination significantly reduces antimicrobial resistance, highlighting it as an essential tool in combating this global and deeply concerning issue.
6. “The macroeconomic impact of a dengue outbreak: case studies from Thailand and Brazil.”
PUBLISHED: PLOS NTDs. June 3, 2024. https://doi.org/10.1371/journal.pntd.0012201
Editorial comment: A compelling model that quantifies economic losses due to dengue outbreaks considers not only direct and indirect costs but also the financial impact of reduced tourism, expressed in billions of US dollars.
7. “Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies”.
PUBLISHED: Lancet Infect Dis. May 31, 2024, with corrections on June 14, 2024. https://doi.org/10.1016/S1473-3099(24)00175-0
Editorial comment: Lyme disease vaccine promising initial results from a Phase 2 clinical trial.
8. “Epitopes in the HA and NA of H5 and H7 avian influenza viruses that are important for antigenic drift”.
PUBLISHED: FEMS Microbiology Reviews, May 11, 2024. https://doi.org/10.1093/femsre/fuae014
Editorial Comment: Analyses included 32 PCV13 sites (488,758 cases) and 15 PCV10 sites (46,386 cases) in 30 countries, primarily high-income (39 sites) using booster dose schedules (41 sites). By six years postPCV10/13 introduction, IPD due to PCV10-type serotypes and PCV10-related serotype (ST)6A declined substantially for both products (children aged <5 years: 83–99% decline; adults aged ≥65 years: 54–96%).
Introduction of PCV10/13 substantially and rapidly reduced IPD in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately 2–3-fold by six years post-PCV10/13 introduction. Sustained increases in ST19A at PCV10 sites and declines at PCV13 sites compared to pre-PCV suggest that PCV13 provides greater net impact than PCV10.
9. “Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalization for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study”.
PUBLISHED: Lancet Infect Dis. April 30, 2024. https://doi.org/10.1016/S1473-3099(24)00215-9
Editorial comment: Early data showing significant effectiveness of Nirsevimab in infants substantially reducing infant hospitalizations for RSV-associated LRTI, severe RSV-associated LRTI requiring oxygen, and all-cause LRTI when given in real-world conditions. These findings offer policy makers and health authorities robust, real-world, population-based evidence to guide the development of strategies for RSV prevention.
10. “Realizing the potential of correlates of protection for vaccine development, licensure and use: short summary”.
PUBLISHED: npj Vaccines. April 29, 2024. https://doi.org/10.1038/s41541-024-00872-6
Editorial comment: Licensing is a key step on the pathway to vaccine utilization but not the final one. The decision to use a new vaccine product will be made by ministry of health policymakers, generally having sought a recommendation from independent advisory committees such as national immunization technical advisory groups (NITAGs). In turn, NITAGs are influenced by the recommendations made by global bodies such as the Strategic Advisory Group of Experts on Immunization (SAGE) and regional immunization technical advisory committees (RITAGs).
In some cases, efficacy data may be available from similar populations to inform policymaking. If they are not, CoP could provide a tool for assessing likely protection in local populations if the strength and reliability of the association between CoP and efficacy within the population of interest is well established.
11. “COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals”.
PUBLISHED: Vaccine. April 2, 2024. https://doi.org/10.1016/j.vaccine.2024.01.100
Editorial comment: The largest study (99 million subjects) by The Global COVID Vaccine Safety (GCoVS) Project comparing adverse event of special interest (AESI) occurring up to 42 days following vaccination with mRNA (BNT162b2 and mRNA-1273) and adenovirus-vector (ChAdOx1) vaccines.
12. “Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomized phase 3 trial”.
PUBLISHED: Lancet. February 10, 2024. https://doi.org/10.1016/S0140-6736(23)02511-4
Editorial comment: Very encouraging results of a second efficacious and safe malaria vaccine, which, alongside the RTS,S vaccine, will bolster efforts in the ongoing fight against this deadly disease, especially in Africa.
